AKT1 and melanoma: Perifosine, an alkylphosphocholine analog and Akt inhibitor, failed to demonstrate a good efficacy in a phase II clinical trial with various side effects and biochemical toxicity, suggesting no further development of this single compound for recurrent melanoma in human [105,123].